Publication | Open Access

1616O Nab-paclitaxel plus gemcitabine versus modified FOLFIRINOX or S-IROX in metastatic or recurrent pancreatic cancer (JCOG1611, GENERATE): A multicentred, randomized, open-label, three-arm, phase II/III trial

Pancreatic CancerGastrointestinal OncologyMedicinePharmacologyCancer TreatmentPhase Ii/iii TrialOncologyRadiation OncologyRecurrent Pancreatic CancerMolecular OncologyGemcitabine Versus